• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Ascentage Pharma Group International - American Depository Shares (NQ:AAPG)

    19.11 -2.93 (-13.29%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Ascentage Pharma Group International - American Depository Shares

    News headline image
    Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Ascentage Pharma to Participate in Three Upcoming Investor Conferences
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Ascentage Pharma Announces Partial Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Ascentage Pharma Announces Closing of U.S. Initial Public Offering
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.